Alcohol-induced defects in hepatic transcytosis may be explained by impaired dynein function

Jennifer L Groebner1, David J Fernandez, Dean J Tuma

  • 1Department of Biology, The Catholic University of America, 620 Michigan Avenue, NE, Washington, DC, 20064, USA.

Insights

Ethanol disrupts protein transport in liver cells by altering microtubule function, leading to impaired liver function. Modulating cellular acetylation may offer a new treatment for alcoholic liver disease.

Area of Science:

  • Hepatology
  • Cell Biology
  • Molecular Mechanisms of Disease

Background:

  • Alcoholic liver disease pathogenesis involves complex molecular mechanisms.
  • Ethanol exposure causes microtubule hyperacetylation and increased stability in hepatic cells.
  • This impacts protein trafficking, including nuclear translocation of transcription factors.

Purpose of the Study:

  • To investigate the effect of ethanol on transcytosis of canalicular proteins in hepatic cells.
  • To elucidate the role of microtubule motor proteins in ethanol-induced hepatotoxicity.
  • To explore potential therapeutic strategies for alcoholic liver disease.

Main Methods:

  • Utilized polarized hepatic WIF-B cells as a model system.
  • Monitored transcytosis of newly synthesized canalicular proteins.
  • Analyzed protein colocalization with dynein/dynactin and binding to microtubules using microscopy and biochemical assays.

Main Results:

  • Canalicular delivery of proteins was impaired in ethanol-treated cells.
  • Stalled proteins colocalized with dynein/dynactin along acetylated microtubules.
  • Ethanol exposure enhanced dynein binding to microtubules, suggesting reduced motor processivity.

Conclusions:

  • Ethanol-induced hyperacetylation impairs microtubule motor function, leading to protein trafficking defects and hepatotoxicity.
  • Enhanced dynein binding to microtubules results in vesicle stalling and impaired canalicular delivery.
  • Modulating cellular acetylation levels may represent a novel therapeutic approach for alcoholic liver disease.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
379
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
30
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
378
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
29
Microtubule Associated Motor Proteins01:32

Microtubule Associated Motor Proteins

Eukaryotic cells have different motor proteins for transporting various cargo within the cell. These motor proteins differ based on the filament they associate with, the direction they move within the cell, and the type of cargo they transport. Motor proteins that associate with microtubules are known as microtubule-associated motor proteins. There are two families of microtubule-associated motor proteins —Kinesins and Dyneins. Both these proteins assist in the transport of cellular...
10.0K